Clark Joshua, Blake Andrew, Vasher Scott, Boucher Richard C, Jones Alexis R, Choi Hee Jae, Albright Benjamin B
University of North Carolina - Chapel Hill, Division of Pulmonary and Critical Care Medicine, USA.
University of North Carolina - Chapel Hill, Division of Gynecology Oncology, USA.
Gynecol Oncol Rep. 2024 Aug 22;55:101486. doi: 10.1016/j.gore.2024.101486. eCollection 2024 Oct.
•Mirvetuximab soravtansine-gynx should be recognized as a cause of drug-induced interstitial lung disease (ILD).•Radiographic manifestations of mirvetuximab soravtansine-gyn induced ILD include organizing pneumonia pattern.•Interstitial lung disease related to mirvetuximab soravtansine-gyn can cause high morbidity.•Corticosteroids are commonly used in drug-induced interstitial lung disease and should be considered when encountering ILD related to mirvetuximab.•Changes to manufacturer dosing guidelines for grade 1 pneumonitis related to mirvetuximab soravtansine-gyn need to be considered.
•应认识到mirvetuximab soravtansine-gynx是药物性间质性肺病(ILD)的一个病因。
•mirvetuximab soravtansine-gyn诱导的ILD的影像学表现包括机化性肺炎模式。
•与mirvetuximab soravtansine-gyn相关的间质性肺病可导致高发病率。
•皮质类固醇常用于药物性间质性肺病,遇到与mirvetuximab相关的ILD时应予以考虑。
•需要考虑对mirvetuximab soravtansine-gyn相关1级肺炎的制造商给药指南进行修改。